Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications

References

• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734.
   PubMed Web of Science ®Google Scholar
• Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928;4(4):285–292.
   PubMedGoogle Scholar
• Lortholary P, Ripault M, Boiron M. Richter's syndrome. Nouv Rev Fr Hematol. 1964;4:456–457.
   PubMedGoogle Scholar
• Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–1392.
   PubMed Web of Science ®Google Scholar
• Muller-Hermelink HK, Montserrat E, Catovsky D, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 127–130.
   Google Scholar
• Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8(10):1640–1645.
   PubMed Web of Science ®Google Scholar
• Morice WG, Kurtin PJ, Hodnefield JM, et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc. 2008;83(7):776–785.
   PubMed Web of Science ®Google Scholar
• Zent CS, Kyasa MJ, Evans R, et al. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer. 2001;92(5):1325–1330.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Smith BR, Weinberg DS, Robert NJ, et al. Circulating monoclonal B lymphocytes in non-Hodgkin's lymphoma. N Engl J Med. 1984;311(23):1476–1481.
   PubMed Web of Science ®Google Scholar
• Arnold A, Cossman J, Bakhshi A, et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med. 1983;309(26):1593–1599.
   PubMed Web of Science ®Google Scholar
• Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed–Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91(23):10962–10966.
   PubMed Web of Science ®Google Scholar
• Archibald WJ, Meacham PJ, Williams AM, et al. Management of melanoma in patients with chronic lymphocytic leukemia. Leuk Res. 2018;71:43–46.
   PubMed Web of Science ®Google Scholar
• Herr MM, Schonfeld SJ, Dores GM, et al. Mutual risks of cutaneous melanoma and specific lymphoid neoplasms: second cancer occurrence and survival. J Natl Cancer Inst. 2018;110(11):1248–1258.
   PubMedGoogle Scholar
• Hisada M. Solid tumors after chronic lymphocytic leukemia. Blood. 2001;98(6):1979–1981.
   PubMed Web of Science ®Google Scholar
• Lam CJK, Curtis RE, Dores GM, et al. Risk factors for melanoma among survivors of non-Hodgkin lymphoma. J Clin Oncol. 2015;33(28):3096–3104.
   PubMed Web of Science ®Google Scholar
• Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010;28(33):4935–4944.
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Gora-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer. 2004;40(3):383–389.
   PubMed Web of Science ®Google Scholar
• Royle JA, Baade PD, Joske D, et al. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer. 2011;105(7):1076–1081.
   PubMed Web of Science ®Google Scholar
• Schollkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer. 2007;121(1):151–156.
   PubMed Web of Science ®Google Scholar
• Travis LB, Curtis RE, Hankey BF, et al. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992;84(18):1422–1427.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A-M, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009;27(6):904–910.
   PubMed Web of Science ®Google Scholar
• Kyasa MJ, Hazlett L, Parrish RS, et al. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma. 2004;45(3):507–513.
   PubMed Web of Science ®Google Scholar
• Levi F, Randimbison L, Te V-C, et al. Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer. 1996;74(11):1847–1850.
   PubMed Web of Science ®Google Scholar
• Agbay RLMC, Jain N, Loghavi S, et al. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2016;91(10):1036–1043.
   PubMed Web of Science ®Google Scholar
• Parikh SA, Habermann TM, Chaffee KG, et al. Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma. Am J Hematol. 2015;90(4):334–338.
   PubMed Web of Science ®Google Scholar
• Parikh SA, Rabe KG, Call TG, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162(6):774–782.
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202–215.
   PubMed Web of Science ®Google Scholar
• Xiao W, Chen WW, Sorbara L, et al. Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion. Hum Pathol. 2016;55:108–116.
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Tadmor T, Robak T, et al. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leuk Lymphoma. 2015;56(7):1949–1958.
   PubMed Web of Science ®Google Scholar
• Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014;123(11):1647–1657.
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131(25):2761–2772.
   PubMed Web of Science ®Google Scholar
• Rabe KG, Ding W, Call TG, et al. Hodgkin transformation of chronic lymphocytic leukemia (CLL): Mayo Clinic experience. Blood. 2013;122(21):1642.
   Web of Science ®Google Scholar
• Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2007;139(3):398–404.
   PubMed Web of Science ®Google Scholar
• Alley CL, Wang E, Dunphy CH, et al. Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature. Arch Pathol Lab Med. 2013;137(4):503–517.
   PubMed Web of Science ®Google Scholar
• Chang H. Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin. Cancer Genet Cytogenet. 2004;148(1):44–48.
   PubMedGoogle Scholar
• Kaufmann H, Ackermann J, Nösslinger T, et al. Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma – a report on two cases. Ann Hematol. 2001;80(8):474–478.
   PubMed Web of Science ®Google Scholar
• Pantic M, Schroettner P, Pfeifer D, et al. Biclonal origin prevails in concomitant chronic lymphocytic leukemia and multiple myeloma. Leukemia. 2010;24(4):885–890.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Schiffer CA. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. Leuk Res. 2009;33(4):561–564.
   PubMed Web of Science ®Google Scholar
• Devi VL, Prabhash K, Malathi M, et al. Uncommon manifestations of common malignancies: case 2. Chronic lymphocytic leukemia and multiple myeloma in the same patient. J Clin Oncol. 2004;22(15):3192–3193.
   PubMed Web of Science ®Google Scholar
• Kern W, Bacher U, Schnittger S, et al. Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B-CLL) and its genetic characterization. Br J Haematol. 2014;164(4):565–569.
   PubMed Web of Science ®Google Scholar
• Plevova K, Francova HS, Burckova K, et al. Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. Haematologica. 2014;99(2):329–338.
   PubMed Web of Science ®Google Scholar
• Sanchez ML. Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood. 2003;102(8):2994–3002.
   PubMed Web of Science ®Google Scholar
• Langerak AW, Groenen PJTA, Brüggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26(10):2159–2171.
   PubMed Web of Science ®Google Scholar
• Lenze D, Müller HH, Hummel M. Considerations for the use of formalin-fixed and paraffin-embedded tissue specimens for clonality analysis. J Hematopathol. 2012;5(1–2):27–34.
   Google Scholar
• Brazdilova K, Plevova K, Skuhrova Francova H, et al. Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. Leukemia. 2018;32(1):234–236.
   PubMed Web of Science ®Google Scholar
• Scarfo L, Dagklis A, Scielzo C, et al. CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? Semin Cancer Biol. 2010;20(6):384–390.
   PubMed Web of Science ®Google Scholar
• Shim YK, Rachel JM, Ghia P, et al. Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding. Blood. 2014;123(9):1319–1326.
   PubMed Web of Science ®Google Scholar
• Vardi A, Dagklis A, Scarfò L, et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood. 2013;121(22):4521–4528.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: International Agency for Research on Cancer; 2017. p. 216–221.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: International Agency for Research on Cancer; 2017. p. 285–290.
   Google Scholar
• Piris MA, Onaindía A, Mollejo M, et al. Splenic marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: International Agency for Research on Cancer; 2017. p. 223–225.
   Google Scholar
• Cook JR, Isaacson PG, Chott A, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: International Agency for Research on Cancer; 2017. p. 259–262.
   Google Scholar
• Campo E, Pileri SA, Jaffe ES, et al. Nodal marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: International Agency for Research on Cancer; 2017. p. 263–265.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: International Agency for Research on Cancer; 2017. p. 232–235.
   Google Scholar
• Jaffe ES, Haris NL, Stein H, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: International Agency for Research on Cancer; 2017. p. 266–273.
   Google Scholar
• Falchi L, Keating MJ, Marom EM, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123(18):2783–2790.
   PubMed Web of Science ®Google Scholar
• Gine E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95(9):1526–1533.
   PubMed Web of Science ®Google Scholar
• Soilleux EJ, Wotherspoon A, Eyre TA, et al. Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review. Histopathology. 2016;69(6):1066–1076.
   PubMed Web of Science ®Google Scholar
• Que TH, Marco JG, Ellis J, et al. Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology. Blood. 1993;82(2):571–575.
   PubMed Web of Science ®Google Scholar
• Oscier D, Else M, Matutes E, et al. The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial. Br J Haematol. 2016;174(5):767–775.
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen S-S, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182–1189.
   PubMed Web of Science ®Google Scholar
• de Rooij MFM, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590–2594.
   PubMed Web of Science ®Google Scholar
• Chen S-S, Chang BY, Chang S, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30(4):833–843.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–1817.
   PubMed Web of Science ®Google Scholar
• Herman SEM, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28(11):2188–2196.
   PubMed Web of Science ®Google Scholar
• Campo E, Catovsky D, Montserrat E, et al. B-cell prolymphocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: International Agency for Research on Cancer; 2017. p. 222–223.
   Google Scholar
• Martinez D, Valera A, Perez NS, et al. Plasmablastic transformation of low-grade B-cell lymphomas: report on 6 cases. Am J Surg Pathol. 2013;37(2):272–281.
   PubMed Web of Science ®Google Scholar
• Stein H, Harris NL, Campo E, et al. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: International Agency for Research on Cancer; 2017. p. 321–322.
   Google Scholar
• Evans AG, Rothberg PG, Burack WR, et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br J Haematol. 2015;171(2):205–209.
   PubMed Web of Science ®Google Scholar
• Williams J, Schned A, Cotelingam JD, et al. Chronic lymphocytic leukemia with coexistent Hodgkin's disease. Implications for the origin of the Reed–Sternberg cell. Am J Surg Pathol. 1991;15(1):33–42.
   PubMed Web of Science ®Google Scholar
• Momose H, Jaffe ES, Shin SS, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed–Sternberg-like cells and possible transformation to Hodgkin's disease. Mediation by Epstein-Barr virus. Am J Surg Pathol. 1992;16(9):859–867.
   PubMed Web of Science ®Google Scholar
• Rubin D, Hudnall SD, Aisenberg A, et al. Richter's transformation of chronic lymphocytic leukemia with Hodgkin's-like cells is associated with Epstein-Barr virus infection. Mod Pathol. 1994;7(1):91–98.
   PubMed Web of Science ®Google Scholar
• Pescarmona E, Pignoloni P, Cerretti R, et al. Hodgkin/Reed–Sternberg cells and Hodgkin's disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background. Virchows Arch. 2000;437(2):129–132.
   PubMed Web of Science ®Google Scholar
• Kuppers R, Sousa AB, Baur AS, et al. Common germinal-center B-cell origin of the malignant cells in two composite lymphomas, involving classical Hodgkin's disease and either follicular lymphoma or B-CLL. Mol Med. 2001;7(5):285–292.
   PubMed Web of Science ®Google Scholar
• Kanzler H, KüPpers R, Helmes S, et al. Hodgkin and Reed–Sternberg-like cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: potential precursors of Hodgkin and Reed–Sternberg cells in Hodgkin's disease. Blood. 2000;95(3):1023–1031.
   PubMed Web of Science ®Google Scholar
• Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007;31(10):1605–1614.
   PubMed Web of Science ®Google Scholar
• Ohno T, Smir BN, Weisenburger DD, et al. Origin of the Hodgkin/Reed–Sternberg cells in chronic lymphocytic leukemia with “Hodgkin's transformation. Blood. 1998;91(5):1757–1761.
   PubMed Web of Science ®Google Scholar
• de Leval L, Vivario M, De Prijck B, et al. Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection. Am J Surg Pathol. 2004;28(5):679–686.
   PubMed Web of Science ®Google Scholar
• Verma V, Giri S, Bhatt VR, et al. Synchronous or metachronous hairy cell leukemia and chronic lymphocytic leukemia: a case series and literature review. Front Oncol. 2016;6:270.
   PubMed Web of Science ®Google Scholar
• Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107(1):175–183.
   PubMed Web of Science ®Google Scholar
• Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006;47(8):1267–1273.
   PubMed Web of Science ®Google Scholar
• Conte MJ, Bowen DA, Wiseman GA, et al. Use of Positron emission tomography-computerized tomography (PET-CT) in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). Leuk Lymphoma. 2013;55:2079–2084.
   Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516–2522.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Salem G, Stephens DM, et al. A single-institution retrospective cohort study of patients treated with R-EPOCH for Richter's transformation of chronic lymphocytic leukemia. Blood. 2015;126(23):2951.
   Web of Science ®Google Scholar
• Langerbeins P, Busch R, Anheier N, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89(12):E239–E243.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I–II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008;26(2):196–203.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Wen S, et al. Phase I–II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymph Myeloma Leuk. 2013;13(5):568–574.
   PubMed Web of Science ®Google Scholar
• Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(18):2211–2217.
   PubMed Web of Science ®Google Scholar
• Tsang M, Shanafelt TD, Call TG, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125(10):1676–1678.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833.
   PubMed Web of Science ®Google Scholar
• Davids MS, Thompson PA, Rogers KA, et al. Initial results of a multicenter phase 2 study of venetoclax in combination with dose‐adjusted R‐epoch for patients with Richter's syndrome (CRC‐043) Hematol Oncol. 2019;37(S2):134–135.
   Google Scholar
• Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129(26):3419–3427.
   PubMed Web of Science ®Google Scholar
• Jain N, Keating MJ, Thompson PA, et al. Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk chronic lymphocytic leukemia (CLL). Blood. 2018;132(Suppl. 1):696.
   Google Scholar
• Turtle CJ, Hay KA, Hanafi LA, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010–3020.
   PubMed Web of Science ®Google Scholar
• Network NCC. National Comprehensive Cancer Network. Chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 2; 2019; [cited 2019 Jan 22]. National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf
   Google Scholar